Detalhe da pesquisa
1.
PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade.
Clin Transl Med
; 14(5): e1655, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38711203
2.
Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases.
Biosens Bioelectron
; 208: 114189, 2022 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35366427
3.
The Expression of the Immunoproteasome Subunit PSMB9 Is Related to Distinct Molecular Subtypes of Uterine Leiomyosarcoma.
Cancers (Basel)
; 14(20)2022 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36291793
4.
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers.
Nat Commun
; 13(1): 4578, 2022 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35931688
5.
Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
Cancers (Basel)
; 13(9)2021 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33922556